Drug Discovery World’s Post

🌟 Meet our new community member: Ary Marsee from HepX Predict! 🌱 Last week, we kicked off our Science and Life Science Validation program. Stay tuned as we introduce our incredible lineup over the coming weeks! HepX Predict is revolutionizing drug development with patented 3D liver organoid technology. By bridging the gap between pre-clinical studies and clinical success, they're tackling the challenge of drug failures head-on. With 70-80% of drugs failing in human trials due to ineffective preclinical models, and liver toxicity contributing to over 20% of these failures, the need for accurate in vitro models is more crucial than ever. Here's to a future of safer and more effective drugs! 💊✨ #DrugDevelopment #Innovation #LifeScience

𝗙𝗿𝗼𝗺 𝟮𝗗 𝘁𝗼 𝟯𝗗: 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗠𝗼𝗱𝗲𝗹𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 https://lnkd.in/dfRtSXjn 👨🔬 "𝘚𝘵𝘢𝘳𝘵𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘴𝘪𝘮𝘱𝘭𝘦 𝟤𝘋 𝘢𝘴𝘴𝘢𝘺𝘴 𝘧𝘰𝘳 𝘳𝘢𝘱𝘪𝘥 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘸𝘦 𝘵𝘩𝘦𝘯 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯 𝘵𝘰 𝘮𝘰𝘳𝘦 𝘤𝘰𝘮𝘱𝘭𝘦𝘹 𝟥𝘋 𝘮𝘰𝘥𝘦𝘭𝘴 𝘵𝘰 𝘥𝘦𝘦𝘱𝘦𝘯 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘯𝘥 𝘦𝘯𝘩𝘢𝘯𝘤𝘦 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺." ✨ 🎥 Check out this short video by @𝗘𝘂𝗴𝗲𝗻𝗶𝗼 𝗙𝗮𝘃𝗮 from German Center for Neurodegenerative Diseases (DZNE) sharing some great practical insights into recent developments in #neuroscience and early drug discovery. Key Points: 1. 2D Models: Quick and stable for initial screening. 2. 3D Models: Provide advanced biological insights but are more complex. 3. Sequential Approach: Begin with simple models, then introduce complexity. 4. Tissue-like Models: Useful but technically challenging for screening. 5. Oncology: Evidence of 3D model utility despite implementation challenges. Thank you so much for your interest. 🔜 Stay Tuned: #CELLIMATALKS will continue for more on #drugdiscovery, #highcontentimaging, and #bigdata applications in #pharmaceuticalresearch. 🔗 If you'd like to delve deeper into this topic with Eugenio, you can listen to the full interview here: https://lnkd.in/dek8aAqU #lifesciences #CellPainting #Healthcare CELLIMA Scientific Service GmbH

🚀 "Launching ASPET Discovery is a critical step in providing more options for researchers as we navigate the open access transition," shares David Jackson, CAE, MBA of American Society for Pharmacology and Experimental Therapeutics - ASPET. Discover how this new journal aligns with the future of scientific publishing and supports ASPET’s mission. 🔗 Read more in our latest A100 article: https://loom.ly/8rreeUk 🔗 And take a deeper dive on our our blog here: https://loom.ly/W9zcYq0 #A100 #OpenAccess

We are happy to share an in-depth review article, authored by Gubra scientists and available now at #DrugDiscoveryToday, on the possibilities offered by 3D light sheet fluorescence microscopy in preclinical and clinical drug discovery process. Read and download the full paper here: https://lnkd.in/dGzCDTzN #LSFM #PreclinicalImaging #DrugDiscovery

Our latest review on 3D Imaging is now available! We describe, how light sheet microscopy is transforming drug discovery, with examples from a range of diseases. 🔬 #DrugDiscovery #3DImaging #LightSheetMicroscopy #Research

The field of preclinical drug development has seen remarkable advancements in recent years, particularly in the development of in vitro models. Assays mimicking human tissue environments play a crucial role in accelerating the drug discovery process. Such models are helping to bridge the gap between preclinical studies and clinical outcomes by improving the predictability of human responses to drug candidate 🧪 Emanuela Costigliola, Chief Marketing Officer at Newcells, spoke to Technology Networks about advances in preclinical drug development and the significance of physiologically relevant models in predicting human responses. Read the full interview to learn more about our work in the field and some of the challenges that our new models solve 👉 https://lnkd.in/eEU3CaUi #Newcells #DrugDevelopment #InVitro

💊 We’re setting new standards in drug discovery. Our DeepMatcher® AI platform utilizes advanced technologies like Flexible Molecular Docking (FMD) to analyze physical interactions between proteins and ligands. Our goal is to accelerate the discovery of first-in-class and best-in-class compounds and reduce the time, cost, and risks involved in drug discovery for Syntekabio’s clients, enabling them to bring important new treatments to patients. 🌍 Explore our latest insights on how we’re redefining the future of drug discovery: https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

The field of preclinical drug development has seen remarkable advancements in recent years, particularly in the development of in vitro models. Assays mimicking human tissue environments play a crucial role in accelerating the drug discovery process. Such models are helping to bridge the gap between preclinical studies and clinical outcomes by improving the predictability of human responses to drug candidates💡 Emanuela Costigliola, Chief Marketing Officer at Newcells, spoke to Technology Networks about advances in preclinical drug development and the significance of physiologically relevant models in predicting human responses. Read the full interview to learn more about our work in the field and some of the challenges that our new models solve 👉 https://lnkd.in/eEU3CaUi #Newcells #DrugDevelopment #InVitro

Preclinical study identified the TRPA1 cannabinoid-binding site and provided new insights into the molecular mechanisms of cannabinoid-induced analgesia: https://lnkd.in/dpfX44_c  #Cannabinoid #TRPA1receptor #PharmacolRes #openaccess #Research 

Oligonucleotides play a critical role in today's biotechnology and medical research, driving advancements in diagnostics, therapeutics, and genetic analysis. In a recent interview with Rizwan Chaudhrey, SK pharmteco's Marc J Jacob, Ph.D. shares our latest capabilities in oligonucleotides.   #biotech #biomanufacturing #advancedtherapies